This extract affects the inhibition of ADP-mediated aggregation, thromboxane, collagen, von Willebrand factor, thrombin and inflammatory mediators. What is more, it blocks the P2Y12 receptor for ADP and limits intracellular granular release of thromboxane, ADP, selectin P and factor 4 (PF4, platelet factor 4). Additionally, it prevents activation of αIIbβIII integrin and inhibits (GP) IIb / IIIa receptor activation. By inhibiting the P2Y12 receptor for ADP, it increases cAMP activity and this results in decreasing intracellular calcium ions concentration. Inhibition of collagen binding process with GP VI as well as von Willebrand factor with GP Ib receptor and decrease in Cβ and Cy2 phospholipase activity are also included in anti-aggregation effects of STE. These phenomena affect the shape of thrombocytha and are reversible while maintaining a level of platelet activity that allows aggregation in case of vascular injury. ZAAX can be used by people with hypersensitivity to salicylates and other non-steroidal anti-inflammatory drugs, with bronchial asthma, with active peptic ulceration.